Collin M. Coon

Biochemistry, Genetics and Molecular Biology · Indiana University

Epigenetics and DNA Methylation Inflammasome and immune disorders Tryptophan and brain disorders Ovarian cancer diagnosis and treatment Ferroptosis and cancer prognosis

Publications

Citations

Est. group size

—

Recurring co-author estimate

Active years

Publishing since 2017

Research summary

AI-generated

Collin M. Coon studies DNA methylation, an epigenetic process that switches genes on and off, and how it relates to cancer. Much of the recent work examines blood-based markers of methylation to predict drug resistance and track treatment responses in ovarian and small-cell lung cancer patients, including trials of hypomethylating drugs. Additional work has covered gene regulation of immune signaling in cancer cells and enzyme engineering for environmental cleanup.

DNA methylation and epigeneticsCancer biomarkers in bloodDrug resistance in ovarian and lung cancerHypomethylating cancer therapiesEnzyme engineering for bioremediation

After several years with little activity, publication output has grown notably since 2024, peaking in 2025.

Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026

Publication cadence

Publications per year over the last 10 years — averaging 2.2/year recently

Recent publications

Blood Based Biomarkers of DNA Methylation Associated with Platinum Resistance in High Grade Serous Ovarian Cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2026
Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients
Pharmaceuticals · 2026
Abstract 7180: DNA methylation profiling of peripheral blood mononuclear cells from small-cell lung cancer patients treated with hypomethylating agent plus carboplatin
Cancer Research · 2025
Abstract 4101: Blood based biomarkers of DNA methylation associated with platinum resistance in high grade serous ovarian cancer
Cancer Research · 2025
Abstract PR-005: ZNFX1 is a master regulator for epigenetic reprograming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells
Cancer Research · 2024
Abstract 2838: ZNFX1 is a master regulator and tumor suppressor in epigenetically induced pathogen mimicry, mitochondrial dysfunction and STING-dependent signaling in cancer
Cancer Research · 2024
Engineering and characterization of dehalogenase enzymes from Delftia acidovorans in bioremediation of perfluorinated compounds
Synthetic and Systems Biotechnology · 2022
Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics
Diseases · 2017

Publishes in

Cancer Research×5
bioRxiv (Cold Spring Harbor Laboratory)×2
Synthetic and Systems Biotechnology×1
Diseases×1
Pharmaceuticals×1

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 11, 2026.

Claim or correct this profile